Abiopharma

Clinical trial NCT07340190: start date: 2026-05-29 → 2026-06-12.

Clinical trial NCT01446133 updates: 1. completion date: 2026-06-30 → 2028-06-30 2. primary completion date: 2026-06-30 → 2028-06-30

Clinical trial NCT05609578 updates: 1. status: RECRUITING → ACTIVE_NOT_RECRUITING 2. primary completion date: 2026-06-01 → 2026-09-30

Clinical trial NCT04060303 updates: 1. completion date: 2024-06-30 → 2024-11-06 2. primary completion date: 2024-06-30 → 2024-11-06 3. enrollment: 599 → 597 participants

Clinical trial NCT07156149 updates: 1. status: RECRUITING → ACTIVE_NOT_RECRUITING 2. enrollment: 50 → 32 participants 3. enrollment type: ESTIMATED → ACTUAL

Clinical trial NCT06850922 updates: 1. status: ACTIVE_NOT_RECRUITING → COMPLETED 2. completion date: 2027-04-30 → 2026-06-19 3. primary completion date: 2027-04-30 → 2026-05-19 4. enrollment: 546 → 388 participants 5. enrollment type: ESTIMATED → ACTUAL

General Announcement: Proposed issue of offshore CNY1,500 million 2.38% notes due 2031 under the S$10B Multicurrency MTN

Disclosure of Interest/Changes in Interest of Substantial Shareholder(s)/Unitholder(s)::Becoming a Substantial Shareholder – Ong Choon Yi (Wang Junyi)

ESS to Accelerate Sodium-Ion Battery Energy Storage System Development Following Surging Customer Interest

Kopin Expands U.S. Operations With New Optics & Photonics Design Center in Dallas, Texas